Yazarlar : Voutsadakis IA, Cairoli A.

Yayın : Leuk Lymphoma.

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21955212

Konu : MDS

Literatür İçeriği :  Abstract

Abstract Chromosome 5q deletion is a chromosomal abnormality that is observed in a sub-set of myelodysplastic syndromes (MDS). When isolated, this abnormality defines a specific clinical syndrome termed MDS associated with isolated deletion 5q, presenting with macrocytic anemia, normal platelet count or slight thrombocytosis, hypolobated megakaryocytes and less than 5% blasts in the bone marrow. MDS with the 5q- deletion have a particular sensitivity to treatment with lenalidomide, a thalidomide analogue. In this paper, molecular changes in 5q- MDS derived from haplo-insufficiency of genes encoded from the deleted region in 5q are reviewed and mechanisms that link these molecular lesions with lenalidomide sensitivity are proposed.

Literatür Arşivi